AGILE high energy detector is composed of a Silicon Tracker, a Mini-Calorimeter, the Anticoincidence and the Data Handling system The Mini-Calorimeter can also work as a stand-alone gamma ray detector in the energy range 250keV-250MeV, with no imaging capabilities, for the detection of transients and gamma ray burst events and for the evaluation of gamma ray background fluctuations.
The Mini-Calorimeter can also work as a stand-alone γ-ray detector in the energy range 250 keV 250 MeV, with no imaging capabilities, for the detection of transients and γ-ray burst events (in cooperation with Super-Agile) and for the evaluation of γ-ray background fluctuations.
This article reviews the state-of-the-art, design, and sensing strategies of upconversion-based sensing platforms, with special attention to upconverting nanoparticles, as well as how the incorporation of these materials into pre-existing diagnostic tests and bioassays have improved their capabilities for the detection of different kinds of analytes.
The newly developed rRT-PCR and cRT-PCR assays provide improved diagnostic capability for the detection and differentiation of ERAV and ERBV.
This confirms the capability for the direct detection of specific target DNA through a signal amplification process.
A hydrogen evolution biocatalyst based on photosystem 1-platinum nanoparticle biocomplexes embedded into a specifically designed redox polymer was used as a model for proving the capability of the developed hydrogen biosensor for the detection of hydrogen upon localized illumination.
This multimodal imaging capability renders CARS microscopy an attractive means for the detection of CTC.
Taken together, the biotransformation system used in this work is applicable for the detection of cofactor regeneration capabilities because this seems to be the limiting step.
These methods have greatly enhanced the capability for surveillance and characterization of influenza viruses and their clinical utility for the detection of respiratory pathogens.
Finally, expression of CD44st could potentially be used as a dominant selectable marker for the detection of the phenotype of multidrug resistance and tumor cell invasion capabilities.
